Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/181646 
Authors: 
Year of Publication: 
2018
Series/Report no.: 
Beiträge zur Jahrestagung des Vereins für Socialpolitik 2018: Digitale Wirtschaft - Session: Poster Session Health and Finance No. P03-V1
Publisher: 
ZBW - Leibniz-Informationszentrum Wirtschaft, Kiel, Hamburg
Abstract: 
This paper studies the effect of a change in the mandatory manufacturer rebate on wholesale prices for pharmaceuticals on competition by parallel imports. First, it analyzes the effect of a manufacturer rebate on competition by parallel imports in a two-country model. An increase in the manufacturer rebate increases the market share of parallel imports. Second, the paper exploits a policy reform in Germany in 2010, which increased the manufacturer rebate by 10 percentage points. Using a data set with prescription drugs with competition from parallel imports, I estimate the e¤ect of the change in the manufacturer rebate on competition by parallel imports. Estimation results suggest that an increase in the manufacturer rebate has increased the market share of parallel imports and the number of importers.
Subjects: 
parallel imports
manufacturer rebate
pharmaceuticals
regulation
JEL: 
F12
I11
I18
F12
I11
I18
Document Type: 
Conference Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.